AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion

AstraZeneca Plc and Bristol Myers Squibb have reportedly held preliminary discussions about a potential merger that could create one of the world’s largest pharmaceutical companies, with a combined market value approaching $400 billion. According to reports, it remains unclear whether negotiations are still ongoing, and neither company has confirmed active talks.

The proposed deal would likely face intense regulatory scrutiny, particularly from U.S. antitrust authorities under President Donald Trump’s administration. Regulators are expected to examine overlapping drug portfolios, competition concerns, and the potential impact on pharmaceutical innovation. Industry experts believe significant asset sales could be required if the merger advances.

The combination would unite two global leaders in oncology, creating a pharmaceutical powerhouse with extensive cancer, cardiovascular, and rare disease portfolios. AstraZeneca has experienced remarkable growth under CEO Pascal Soriot, with its market value climbing sharply over the past 14 years. The company recently reported strong quarterly results, driven by demand for its cancer and rare disease treatments. In 2025, oncology products generated approximately $25 billion in revenue, nearly half of AstraZeneca’s total sales.

Bristol Myers Squibb is also heavily focused on cancer therapies, with oncology accounting for more than 40% of its revenue during the first half of 2026. However, the company faces upcoming patent expirations for blockbuster medicines such as Opdivo and Eliquis, prompting increased investment in newer products including blood thinner milvexian, anemia treatment Reblozyl, and heart drug Camzyos.

Legal experts note that major pharmaceutical mergers continue to face bipartisan regulatory scrutiny in the United States. During President Trump’s previous administration, Bristol Myers’ $80 billion acquisition of Celgene required the divestiture of psoriasis drug Otezla to secure approval, highlighting the challenges another large-scale transaction could encounter.

A potential AstraZeneca-Bristol Myers merger would also carry strategic implications, as a UK-based company would effectively acquire one of America’s leading pharmaceutical firms. Large pharmaceutical mergers have become increasingly uncommon in recent years due to antitrust concerns, pricing pressures, and heightened regulatory oversight, making any agreement between the two companies one of the industry's most closely watched deals.